Universitair Ziekenhuis Brussel
Jette, Brussels Capital, 1090, Belgium
Location status: Recruiting
NCT Number: NCT07347743
This study aims to demonstrate that a dietary supplement, which contains two strains of the probiotic L. reuteri is safe, well tolerated and able to reduce the incidence of colic and excessive crying/fussiness in healthy infants. Additionally, the study aims to investigate if children with this probiotic supplement have better stool characteristics and a more beneficial composition of the fecal and skin flora than children given a placebo during the first 3 months of life.
Interested in participating?
Request Info1 day–14 day
All sexes
Interventional
Not applicable
Jette, Brussels Capital, 1090, Belgium
Location status: Recruiting
This study is a double-blind, randomized, placebo-controlled trial conducted at UZ Brussel to evaluate the safety and preventive efficacy of a dietary supplement containing two probiotic strains of Limosilactobacillus reuteri on excessive crying and the development of infantile colic in healthy newborns.
Recent systematic reviews and meta-analyses have shown that supplementation with certain strains of L. reuteri significantly reduces crying and fussing time in infants. A novel formulation combining those strains was developed to achieve a potentially enhanced effect on infant distress symptoms. This study investigates whether early supplementation, initiated within the first week of life, is safe and effective during the first three months of life.
Healthy, full-term infants (≥37 weeks' gestation) aged 1-14 days at inclusion are eligible. Participants are randomized to receive either placebo plus vitamin D (400 IU) or L. reuteri plus vitamin D (400 IU) for a maximum of 98 days, until approximately 3 months of age.
Study visits include a baseline visit (day 1-14), a midway visit at 6 weeks, an end-of-intervention visit at 3 months, and a long-term follow-up at 1 year. Additional telephone contacts are triggered by infant day diaries.
The primary outcomes are peak crying and fussing time at 6 weeks of age and the occurrence of infantile colic during the first 3 months of life. Secondary outcomes include infant quality of life (ITQOL™), parental stress, parental satisfaction, crying and fussiness patterns, and the presence of atopic dermatitis. Exploratory outcomes assess changes in the intestinal microbiome, stool characteristics, biomarkers, growth, and allergy-related parameters.
The primary hypothesis is that daily supplementation with the two strains of L. reuteri reduces the incidence of infantile colic and peak crying time at 6 weeks. Secondary hypotheses propose microbiome modulation leading to reduced distress, improved infant quality of life, and lower parental stress.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Each participant in this intervention group gets 5 drops per day, containing the two probiotic Limosilactobacillus reuteri strains and 400 IU of Vitamin D
Each participant in this intervention group gets 5 drops per day, containing only 400 IU of Vitamin D.
Time frame: 6 weeks
Peak measured crying time at 6 (±1) weeks according to the prospectively kept baby day diary
Time frame: 3 months
The criteria for infant colic are:
Time frame: 6 weeks
Peak measured fussiness time at the age of 6 (±1) weeks according to the prospectively kept baby day diary.
Time frame: 3 months
Overall (estimated + measured) crying and/or fussiness time in the first 3 months (±1 week) of life.
Time frame: 3 months
Overall measured and/or estimated unconsolable crying time in the first 3 months (±1 week) of life
Time frame: 3 months
Parental stress as measured by the Parental Stress Scale (PSS) at 6 (±1) weeks and 3 months (±1 week) of both (if applicable) caregivers. Parents can indicate the degree to which they agree or disagree with the statements in this questionnaire, ranging from strongly disagree (1 point) to strongly agree (5 points). Total scores range from 18 points (low score signify a low level of stress) to 90 points (high score signify a high level of stress).
Time frame: 12 months
Infant and toddler quality of life questionnaire(ITQOL™) at 3 months (±1 week) and of 12 months (±2 weeks) age. ITQOL is scored on a scale from 0 to 100, where higher scores mean better health/quality of life.
Time frame: 3 months
Parental satisfaction scale measured by a 5-point Likert scale at 6 (±1) weeks and 3 months (±1 week). A scale where parents indicate how satisfied they are with their baby's current level of crying and fussing, with a minimum score of 2 and maximum score of 10. Parents who are very dissatisfied have a low score, while parents who are very satisfied have a high score.
Time frame: 12 months
Presence and degree of atopic dermatitis (AD, measured via SCORAD) at 3 months (±1 week) and 12 months (±2 weeks) of age. The score ranges from 0 to 103 and is used to determine the stages of AD severity. Where a score lower than 25 is seen as mild state, 25-50 is a moderate state and >50 is a severe state.
Time frame: 3 months
Assessed by the parents in a continuous daily bowel diary over the study period using the Brussels infant and toddler stool scale (BITSS). BITSS was validated as a reliable instrument to assess stools of non-toilet trained children There are 4 possible answers: A: Hard stool, B: Formed stool, C: Loose Stool and D: Watery stool, based on pictures.
Time frame: 3 months
assessed by the parents and day care centers in a continuous daily bowel diary over the study period using the BITSS
Time frame: 3 months
Fecal calprotectin at 6 (±1) weeks and 3 months (±1 week) of age
Time frame: 3 months
Morning saliva melatonin level at 6 (±1) weeks and 3 months (±1 week) of age
Time frame: 3 months
Number of (serious) adverse events throughout the study period. Parents are asked to provide detailed information on any adverse events their child may experience during the study. For each event, the diagnosis, sign, or symptom is written down, as well as the date the event started and ended. Parents should also describe the severity of the event, rating it as mild, moderate, or severe, and provide their assessment of its relationship to the study product, categorizing it as unrelated, unlikely, probable, or related. Moreover the outcome of the event should be specified, such as fatal, not resolved, resolved, resolved with sequelae, resolving, or unknown. Lastly, parents should report any actions taken regarding the study product, including whether the dose was unchanged, reduced, increased, temporarily suspended, or definitively withdrawn, or if there was any concomitant medication given to the child or no action was required.
Time frame: 3 months
Weight for age z score at each study visit
Time frame: 3 months
Stool pH at 6 (±1) weeks and 3 months (±1 week)
Time frame: 3 months
SCFA analysis at 6 (±1) weeks and 3 months (±1 week) of age. Concentrations of both straight-chain SCFA as branched-chain SCFA will be measured to be associated with the health status of the gut microbiota.
Time frame: 12 months
16S ribosomal RNA (rRNA) gene amplicon sequencing of skin microbiome (or shotgun metagenomics sequencing if the budget allows for this) at 6 weeks, 3 months and 12 months. To gain insight into the quantitative and qualitative abundance of microbial composition and diversity
Time frame: 3 months
16S ribosomal RNA (rRNA) gene amplicon sequencing of stool microbiome (or shotgun metagenomics sequencing if the budget allows for this) at 6 weeks, 3 months. To gain insight into the quantitative and qualitative abundance of microbial composition and diversity
Time frame: 3 months
Height for age Z-score at each study visit
Time frame: 3 months
Weight for height z score at each study visit
Contact information is provided by the study sponsor or research team.
Koen Huysentruyt, Pediatric Gastroenterologist
CONTACT
+32 02/476.37.17
Leontien Depoorter, Resident Pediatric Pulmonology
CONTACT
+32 02/801.25.58
Universitair Ziekenhuis Brussel
Other
Double-blind, Randomized Placebo-controlled Trial for the Preventive Effect of Limosilactobacillus Reuteri (L. Reuteri) on Excessive Crying and Colic in Healthy Infants.
Acronym: ProtectPrevent
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01849991
Behavior, Carbohydrate Metabolism, Inborn Errors
Houston, Texas, United States
View Trial DetailsNCT00796523
Behavior, Colic
Columbus, Ohio, United States
View Trial DetailsNCT04537494
Colic, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Toronto, Ontario, Canada
View Trial DetailsNCT06967870
Colic, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Bursa, Osmangazi, Turkey (Türkiye)
View Trial Details